NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $1.13 -0.01 (-0.45%) As of 07/8/2025 03:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Connect Biopharma Stock (NASDAQ:CNTB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Connect Biopharma alerts:Sign Up Key Stats Today's Range$1.11▼$1.1850-Day Range$0.73▼$1.1452-Week Range$0.51▼$1.60Volume48,457 shsAverage Volume57,104 shsMarket Capitalization$63.06 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview Connect Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody and small-molecule therapies for immune-mediated diseases. Since its inception, the company has pursued a precision immunology approach, applying advanced screening and antibody engineering technologies to identify targets implicated in inflammatory pathways. Connect Biopharma’s research platform is designed to accelerate the transition of promising candidates from laboratory to clinical testing. The company’s lead programs include CBP-201, a fully human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), currently in Phase II trials for ulcerative colitis and psoriasis, and CBP-307, an oral sphingosine-1-phosphate receptor modulator in development for inflammatory bowel disease. Both candidates leverage proprietary binding and pharmacokinetic optimization to achieve sustained target engagement while minimizing off-target effects. These pipelines are supported by a robust preclinical portfolio aimed at additional cytokine and chemokine targets. Headquartered in Hong Kong with research facilities in Shanghai and clinical operations in the United States, Connect Biopharma conducts global studies spanning Asia, Europe and North America. The company maintains strategic partnerships with academic institutions and contract research organizations to advance its therapeutic candidates through regulatory milestones. Its network of external collaborators aids in biomarker development and patient stratification strategies to enhance trial efficiency. Connect Biopharma’s leadership team comprises seasoned executives and scientific founders with deep experience in immunology, biologics development and global clinical operations. Guided by its mission to bring transformative treatments to patients with chronic inflammatory disorders, the company continues to expand its portfolio and advance novel assets toward commercialization.AI Generated. May Contain Errors. Read More Connect Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCNTB MarketRank™: Connect Biopharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 328th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingConnect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageConnect Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Connect Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Connect Biopharma are expected to decrease in the coming year, from ($0.22) to ($0.32) per share.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Connect Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.04% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. News and Social Media1.5 / 5News Sentiment-0.30 News SentimentConnect Biopharma has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Connect Biopharma this week, compared to 0 articles on an average week.Search Interest5 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTB Stock News HeadlinesConnect Biopharma Holdings Limited (CNTB) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comCNTB Connect Biopharma Holdings Limited - Seeking AlphaJuly 2, 2025 | seekingalpha.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | Crypto 101 Media (Ad)Connect Biopharma Reports Positive Clinical Results for Rademikibart in Eosinophilic-Driven Type 2 Asthma PatientsJune 15, 2025 | nasdaq.comConnect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressJune 13, 2025 | globenewswire.comConnect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressJune 3, 2025 | globenewswire.comConnect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International ConferenceMay 20, 2025 | globenewswire.comConnect Biopharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comSee More Headlines CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $1.38 at the beginning of the year. Since then, CNTB stock has decreased by 17.8% and is now trading at $1.1349. How were Connect Biopharma's earnings last quarter? Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $150 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC acted as the underwriters for the IPO. How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Connect Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings5/15/2025Today7/09/2025Next Earnings (Estimated)9/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTB CIK1835268 Webwww.connectbiopharm.com Phone18587271045Fax+1 8586147007Employees110Year FoundedN/APrice Target and Rating Average Price Target for Connect Biopharma$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+516.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$26.03 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book0.68Miscellaneous Outstanding Shares55,560,000Free Float43,004,000Market Cap$63.06 million OptionableOptionable Beta-0.20 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:CNTB) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.